PMID: 42571323

Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial.

Jiménez-Mausbach Martí, Tijms Betty M, Paterson Clare, Refsgaard Jan Christian

Alzheimer's & dementia (Amsterdam, Netherlands) · 2026

Vol. 18, Issue 3, pp. e70432

View on PubMedDOI

This entry links to third-party literature. For research use only.

For research use only. This index links to third-party literature. Nothing here constitutes medical advice.